News
Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
NEW YORK, July 21st, 2009 – Exosome Diagnostics, Inc., the developer of non-invasive molecular oncology diagnostics to aid in early cancer detection and therapeutic selection, announced today that Greg Zdechlik has been named Chief Operating Officer. More…
Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations
NEW YORK, June 22nd, 2009 – Exosome Diagnostics, Inc. (“ExosomeDX”) and DxS Ltd. (“DxS”) today announced that they will collaborate on the development of blood based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. More…
Urine Exosomes Found to Contain Key Prostate Cancer Genetic Markers
NEW YORK, May 13th, 2009 – Exosome Diagnostics, Inc. today announced discoveries published in the British Journal of Cancer Research that two biomarkers for prostate cancer, TMPRSS2:ERG and PCA3, can be detected from exosomes in the urine. This information could help doctors decide which prostate cancers are aggressive and require rapid treatment. More…
Exosome Diagnostics Announces Tiffany Olson Will Join Its Board of Directors
NEW YORK, March 2nd, 2009 – Exosome Diagnostics, Inc., the developer of proprietary genetics-based diagnostic tests, today announced that Tiffany Olson has joined the Company’s Board of Directors. Ms. Olson is the former President and CEO of Roche Diagnostics Corporation. More…
Exosome Diagnostics Announces that Lester Crawford, DVM, Ph.D. is joining its Scientific Advisory Board
NEW YORK, Jan. 12, 2009 – Exosome Diagnostics, Inc. today announced that Lester Crawford, DVM, Ph.D. has joined the company’s Scientific Advisory Board. More…
Exosome Diagnostics Announces Dr. John Holaday Will Join Its Board of Directors
NEW YORK, Dec. 17, 2008 – Exosome Diagnostics, Inc., the developer of proprietary genetics-based diagnostic tests with applications in oncology and metabolic disease, today announced that John Holaday, Ph.D. has joined the Company’s Scientific Board of Directors. More…
Exosome Diagnostics Developing Blood Test to Help Monitor Status and Eligibility of Brain Tumors to Drug Treatments.
NEW YORK, Nov. 17, 2008 – Tiny vesicles called exosomes released into the bloodstream from aggressive brain tumors contain genetic signatures that may help guide future diagnosis and treatment of this deadly disease. More...
Exosome Diagnostics Announces That Roger Henriksson, M.D., Ph.D. is Joining its Scientific Advisory Board.
NEW YORK, Oct. 6, 2008 – Exosome Diagnostics, Inc. today announced that Roger Henriksson, M.D., Ph.D. has joined the company’s scientific advisory board. More...
Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
NEW YORK, Sept. 12, 2008 – Exosome Diagnostics, Inc. today announced the appointment of Johan Skog, Ph.D., as director of genetics research. In this role, Dr. Skog will oversee the research program that underlies the company’s development of its blood-based diagnostics that can identify cancer-specific genetic mutations. More...
Exosome Diagnostics Announces Formation of its Scientific Advisory Board
NEW YORK, Sept. 08, 2008 – Exosome Diagnostics, Inc. today announced the formation of its scientific advisory board with the appointments of Dennis Brown, Ph.D.; Xandra Breakefield, Ph.D.; and Richard L. Edelson, M.D. More...
Exosome Diagnostics Announces Additions to Management Team
NEW YORK, Sept. 3, 2008 – Exosome Diagnostics, Inc. today announced additions to its management team as the company moves forward with development of its blood-based diagnostics that can identify cancer-specific genetic mutations. More...